Q4 2024 Co-Diagnostics Inc Earnings Call Transcript
Key Points
- Co-Diagnostics Inc (CODX) advanced the development of the Co-Dx PCR platform and associated test pipeline in 2024, strengthening the foundation for commercialization.
- The company completed its first application to the U.S. FDA for 510(k) clearance for the Co-Dx PCR Pro instrument and COVID-19 test for over-the-counter use.
- Co-Diagnostics Inc (CODX) has identified a procedure to simplify and affordably prepare patient TB samples for PCR analysis, with clinical evaluations planned in South Africa and India.
- The company inaugurated new manufacturing facilities in Utah and India, enhancing its capacity to support commercialization efforts and meet anticipated demand.
- Co-Diagnostics Inc (CODX) received a test license from the CDSCO in India, a vital step towards regulatory submission and IVD clearance for its products.
- Total revenue for fiscal year 2024 decreased to $3.9 million from $6.8 million in the prior year.
- The company experienced a net loss of $37.6 million in 2024, compared to a net loss of $35.3 million in the prior year.
- Legal expenses increased significantly to $7.0 million in 2024 due to funding the defense of securities class action lawsuits.
- The company had to withdraw its 510(k) submission for the COVID-19 test due to the need for updated clinical data, delaying regulatory clearance.
- Adjusted EBITDA was a loss of $33.5 million in 2024, slightly higher than the adjusted EBITDA loss of $33.0 million in the prior year.
Good day, and welcome to the Co-Diagnostics fourth quarter and full year 2024 earnings conference call. (Operator Instructions). Please note that this event is being recorded.
I would now like to turn the conference over to Andrew Benson, Investor Relations. Please go ahead, sir.
Good afternoon, everyone, and thank you for participating in today's conference call. On the line today from Co-Diagnostics, we have Dwight Egan, Chief Executive Officer; and Brian Brown, Chief Financial Officer.
Earlier today, Co-Diagnostics released financial results from the fourth quarter and full year ended December 31, 2024, and A copy of the press release is available on the company's website. We will begin the call with management's prepared remarks and then open the call to analyst Q&A.
Before we begin, we would like to inform the listeners that certain statements made by Co-Diagnostics during this call, which are not historical facts, are forward-looking statements. This include statements
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
